ramelteon / Generic mfg. |
2007-002875-15: A Single-Center, Randomized, Double-Blind, Double-Dummy Placebo Controlled, Cross-Over Study to Investigate the Next Morning Effects of Ramelteon (8mg), Zopiclone (7.5mg) and Placebo on Actual Driving Performance, Memory Functioning, Psychomotor Performance in Adults with Chronic Insomnia |
|
|
| Ongoing | 4 | 30 | Europe | Ramelteon, zopiclone, TAK-375, Zimovane, Zimovane | Takeda | insomnia characterised by difficulty with sleep onset | | | | |
| Recruiting | 4 | 506 | US | Ramelteon 8mg | Centennial Medical Center | Delirium | 03/25 | 12/25 | | |
NCT06512363: A Study of Ramelteon in Chinese Patients With Chronic Insomnia |
|
|
| Not yet recruiting | 3 | 280 | NA | Ramelteon, Ramelteon placebo | Nanjing Chia-tai Tianqing Pharmaceutical | Chronic Insomnia | 12/26 | 12/26 | | |
NCT04470297: Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19 |
|
|
| Not yet recruiting | 2 | 100 | NA | Ramelteon 8mg | Associação Fundo de Incentivo à Pesquisa | Covid19, Lung Injury | 11/20 | 03/21 | | |
NCT02691013: The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery |
|
|
| Active, not recruiting | N/A | 120 | NA | Ramelteon, Placebo | University of California, San Diego | Delirium, Sleep Deprivation | 12/17 | 12/22 | | |
Hetlioz (tasimelteon) / Vanda |
2015-003198-14: A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of multiple oral doses of tasimelteon and matching placebo in travelers with Jet Lag Disorder |
|
|
| Ongoing | 3 | 400 | Europe | Tasimelteon (HELTLIOZ®), VEC-162, Capsule, HELTLIOZ® | Vanda Pharmaceuticals Inc, Vanda Pharmaceuticals Inc | Jet Lag Disorder (JLD), Not possible to specify | | | | |
NCT01218789 / 2010-020912-12: Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception |
|
|
| Active, not recruiting | 3 | 140 | Europe | tasimelteon, VEC-162 | Vanda Pharmaceuticals | Non 24 Hour Sleep Wake Disorder | 12/24 | 12/24 | | |
2021-005475-40: A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD) |
|
|
| Not yet recruiting | 3 | 300 | Europe | Tasimelteon, VEC-162, Capsule, hard | Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Inc. | Delayed Sleep-Wake Phase Disorder (DSWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05361707: Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances |
|
|
| Recruiting | 3 | 100 | US | Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Vanda Pharmaceuticals | Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance | 07/25 | 07/25 | | |
NCT04652882: Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |
|
|
| Recruiting | 3 | 300 | Europe, US, RoW | Tasimelteon, Placebo | Vanda Pharmaceuticals | Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders | 12/24 | 12/25 | | |
NCT06323655: Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects |
|
|
| Completed | 1 | 48 | Canada | Tasimelteon, Active Control Placebo, Tasimelteon Placebo, Active Control | Vanda Pharmaceuticals | Healthy Volunteers | 08/18 | 08/18 | | |
NCT05572281: Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers |
|
|
| Completed | 1 | 36 | US | Tasimelteon Oral Capsule, Tasimelteon Oral Suspension | Vanda Pharmaceuticals | Healthy | 06/22 | 06/22 | | |
RBD, NCT05922995: The Effects of Tasimelteon in Participants With REM Behavior Disorder |
|
|
| Not yet recruiting | 1 | 20 | US | Tasimelteon, Hetlioz | Brigham and Women's Hospital, Vanda Pharmaceuticals | REM Behavior Disorder | 09/26 | 12/28 | | |
agomelatine / Generic mfg. |
2009-010642-57: “Efficacy and safety of ValdoxanR given orally once a day for 24 weeks in patients with Major Depressive Disorder.” Open, national, multicentric clinical trial for the evaluation of the antidepressant efficacy and tolerability of ValdoxanR and its additional clinical benefits for depressed patients. |
|
|
| Ongoing | 4 | 160 | Europe | S20098, S20098, Film-coated tablet, VALDOXAN | Servier Slovensko, spol. s.r.o. | Major Depressive Disorder | | | | |
2009-016953-16: Depressions-Spektrums-Störung und differenzielle Effekte neuerer Antidepressiva auf die Verkehrssicherheit |
|
|
| Ongoing | 4 | 120 | Europe | Cipralex, Solvex, Remergil, Elontril, Valdoxan, Tablet, Cipralex, Solvex, Remergil, Elontril, Valdoxan | Inn-Salzach-Klinikum gGmbH | Spectrum of depressive diseases, ICD-10: F32.x, F33.x | | | | |
2013-003370-27: Functional changes in the brain after application of antidepressants and their clinical impact, their relation to the stress hormone system and to the enterobacteria Bildgebung des Kopfes nach Behandlung mit Antidepressiva sowie der Zusammenhang zum klinischen Verlauf, zum Stresshormonsystem und zu den Darmbakterien |
|
|
| Ongoing | 4 | 80 | Europe | Coated tablet, Mirtazapin-CT, Cipralex, Valdoxan | Rainer Rupprecht, Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg am Bezirksklinikum, Universität(sklinikum) Regensburg, Bundesministerium für Bildung und Forschung | Major Depressive Disorder is a chronic stress related disorder characterized by depressed mood and by vegetative and cognitive symptoms. Moreover, genetic, neuroendocrine and neurochemical biomarkers may predict impaired processing and regulation of emotions related to major depression as well as antidepressant treatment response in general. There is evidence, that the gut microbiome may influence stress, anxiety and depression-related behavior via effects on the host´s neuroendocrine system. Depression ist eine stressassoziierte Störung, charakterisiert durch gedrückte Stimmung, vegetative und kognitive Symptome. Außerdem könnten genetische, neuroendokrine, -chemische Biomarker Vorhersagen treffen über gestörte Verarbeitung/Regulation von Emotionen in Zusammenhang mit Depression sowie über das Ansprechen auf antidepressive Therapie. Es gibt Anhaltspunkte, dass das Dickdarm-Mikrobiom womöglich Einfluss hat auf Stress und Angst durch Effekte auf das neuroendokrine System des Wirtes., Disease characterized by depressed mood and by vegetative Symptoms (e.g. sleep disturbance, dimished appetite) and cognitive symptoms (e.g. reduced attention) Krankheitsbild charakterisiert durch gedrückte Stimmung, vegetative (z.B. Schlafstörungen, Appetitlosigkeit) und kognitive Symptome (z.B. Aufmerksamkeitsstörungen)., Diseases [C] - Nervous System Diseases [C10] | | | | |
2008-008220-32: Efficacité clinique de VALDOXAN dans les conditions de pratique quotidienne (efficience) chez des patients déprimés, en switch ou naïfs de traitement Etude clinique interventionelle de phase IV, multicentrique, ouverte. Etude VALDOXAN D-CHANGE. |
|
|
| Ongoing | 4 | 4000 | Europe | S20098, S20098, VALDOXAN, VALDOXAN | EUTHERAPIE pour le compte du promoteur Les Laboratoires Servier | Episode depressif majeur | | | | |
2009-010112-15: Effets cliniques de VALDOXAN® (25 ou 50mg) à long terme chez des patients déprimés - Etude clinique, nationale, interventionnelle de phase IV, multicentrique, réalisée en ouvert.Etude Valdoxan D - EXTENSION |
|
|
| Ongoing | 4 | 3200 | Europe | S20098, S20098, VALDOXAN, VALDOXAN | EUTHERAPIE pour le compte du promoteur Les Laboratoires Servier | Episode depressif majeur | | | | |
2009-012560-14: Réponse au VALDOXAN® et restauration des rythmes de vie dans la dépression unipolaire : Etude VALDOXAN® D-Rhythm.Etude clinique interventionnelle de phase IV, multicentrique |
|
|
| Ongoing | 4 | 1600 | Europe | S20098, S20098, VALDOXAN, VALDOXAN | EUTHERAPIE / Les Laboratoires Servier | Episode depressif majeur | | | | |
2010-021044-17: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study. |
|
|
| Ongoing | 4 | 60 | Europe | agomelatin, Valdoxan, Valdoxan | Medizinische Universität Wien | Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD) | | | | |
2010-019423-61: GENRAS(GENetics of Response to Agomelatine vs. EScitalopram) |
|
|
| Ongoing | 4 | 400 | Europe | CIPRALEX - Filmtabletten 10 mg, VALDOXAN 25 mg - Filmtabletten, CIPRALEX - Filmtabletten 10 mg, VALDOXAN 25 mg - Filmtabletten, CIPRALEX - Filmtabletten 10 mg, VALDOXAN 25 mg - Filmtabletten | Medizinische Universität Wien,Univ.Klinik f.Psychiatrie und Psychotherapie | depressive disorder | | | | |
| Ongoing | 4 | 40 | Europe | Valdoxan, Trevilor retard, Valdoxan, Trevilor retard, Valdoxan, Trevilor retard | Inn-Salzach-Klinikum gGmbH | Diagnosis of depression; ICD-10: F32.x, F33.x | | | | |
2017-000990-35: Effects of the antidepressive therapy with Agomelatin and Escitalopram in people with depression and epilepsy Effetti della terapia antidepressiva utilizzando Agomelatina ed Escitalopram in persone con depressione ed epilessia |
|
|
| Ongoing | 4 | 208 | Europe | Agomelatina, Escitalopram, n.a., Film-coated tablet, VALDOXAN - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/PVC) 7 COMPRESSE, ESCITALOPRAM ACCORD - " 10 MG COMPRESSE RIVESTITE CON FILM " 98 COMPRESSE IN BLISTER AL/AL | DIP. MEDICINA DEI SISTEMI UNIVERSITÃ DEGLI STUDI DI ROMA TOR VERGATA | Depression in patients affected by epilepsy Depressione in pazienti affetti da epilessia, Depression in person with epilepsy Depressione in persone con epilessia, Diseases [C] - Nervous System Diseases [C10] | | | | |
ChiCTR2200066866: Efficacy and safety of Agomelatine monotherapy in the treatment of depression: a multicenter, open-ended study |
|
|
| Completed | 4 | 93 | | Agomelatine monotherapy | Beijing Anding Hospital Affiliated to Capital Medical University; Beijing Anding Hospital Affiliated to Capital Medical University, Jiangsu Hausen Pharmaceutical Co., LTD | Major depressive disorder | | | | |
ChiCTR1800020182: A control study for sertraline and agomelatine on insomnia symptoms in patients with depression |
|
|
| Recruiting | 4 | 80 | | agomelatine 25-75mg per day before sleep ;sertraline 50-200mg per day before sleep | Kangci Hospital of Jiaxing; Level of the institution:, Subject funds of Tongxiang | Dpression | | | | |
ChiCTR2100045530: A preliminary study on the efficacy and safety of proton pump inhibitors combined with agomelatine in the treatment of gastroesophageal reflux disease |
|
|
| Recruiting | 4 | 80 | | On the basis of proton pump inhibitor (rabeprazole 20mg, orally, 1 day), agomelatine 25mg/d was added, orally before bedtime ;On the basis of proton pump inhibitor (rabeprazole 20mg, orally, 1/ day) treatment, soothing agents were added, orally before bedtime | Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Jiangsu Hansoh Pharmaceutical Group Co. Ltd | Gastroesophageal reflux disease (GERD) | | | | |
NCT04589143: A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine |
|
|
| Completed | 4 | 137 | RoW | Agomelatine, Placebos | Central South University | Major Depressive Disorder | 12/22 | 01/23 | | |
ChiCTR1800018822: A randomized, double-blind, controlled trial for investigation of the improvement of agomelatine combined cognitive behavioral therapy in patients with chronic insomnia with mild depression |
|
|
| Recruiting | 4 | 300 | | placebo pill ;Agomelatine pill ;Zolpidem Tartrate pill | Changzheng Hospital of Second Miliatary Medical University; Changzheng Hospital of Second Miliatary Medical University, research projects | chronic insomnia and depression | | | | |
ACTRN12621000601831: Agomelatine in Depression: An Open-Label Study of Agomelatine in Adults with Major Depressive Disorder |
|
|
| Completed | 4 | 30 | | | Alto Neuroscience (Australia) Pty Ltd, Alto Neuroscience (Australia) Pty Ltd | Major Depressive Disorder | | | | |
ChiCTR2100048875: A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of agomelatine in patients with rapid eye movement (REM) sleep behavior disorder (RBD) |
|
|
| Not yet recruiting | 4 | 50 | | Agomelatine 25mg/d, oral treatment before sleep, the dose was increased to 50mg/d after 2 weeks of treatment if no liver impairment occurs ;Placebo, oral treatment before sleep | Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Jiangsu Hansoh Pharmaceutical Group Co., Ltd | Rapid eye movement (REM) sleep behavior disorder (RBD) | | | | |
ChiCTR2000032518: Efficacy and safety of agomelatine combined with SSRIs in depressive disorder: a randomized controlled trial |
|
|
| Recruiting | 4 | 120 | | Treat with the combination of SSRIs (sertraline or escitalopram) in the first 6 weeks.Those whose efficacy is well in the first stage of treatment will continue to receive the original drug and the same dose.Others who did not respond to the treatment will be given a combination of sertraline or esc ;Treat with Agomelatine in the first 6 weeks.Those whose efficacy is well in the first stage of treatment will continue to receive the original drug and the same dose.Others who did not respond to the treatment will be given a combination of sertraline or escitalopram with agomelatine. | Shandong Mental Health Center; Shandong Mental Health Center, Teachers' Scientific Research Support Fund of Jining Medical College | Major Depressive Disorder | | | | |
ChiCTR2200061464: The use of real-world evidence for evaluating the efficacy and side effects of agomelatine in the treatment of major depressive disorder |
|
|
| Not yet recruiting | 4 | 1380 | | None | Zhongda Hospital, School of Medicine, Southeast University; Zhongda Hospital, School of Medicine, Southeast University, self-raised | major depressive disorder (MDD) | | | | |
NCT05646264: A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia |
|
|
| Recruiting | 4 | 220 | RoW | Agomelatine | Shanghai Mental Health Center, Tianjin Anding Hospital | Schizophrenia, Negative Symptoms in Schizophrenia | 08/23 | 08/23 | | |
| Not yet recruiting | 4 | 420 | NA | Agomelatine, Agomelatine Tablets, Placebo Tablets, Placebo Placebo | First Affiliated Hospital, Sun Yat-Sen University | Depression, Acute Ischemic Stroke | 05/24 | 05/24 | | |
ChiCTR-TRC-11001668: Efficacy and safety of agomelatine with flexible dose (25 mg/day with potential adjustment at 50 mg) given orally for 8 weeks in out-patients with Major Depressive Disorder. |
|
|
| Completed | 3 | 628 | | Oral Valdoxan, Agomelatine, 25 or 50mg, tablets ;Oral Prozac, Fluoxetine, 20 or 40mg capsules | Institut de Recherche Internationales Servier; Level of the institution:, Institut de Recherche Internationales Servier | Major Depressive Disorder | | | | |
2011-005320-17: Effects of agomelatine on emotional experiences in depressed adults patients as compared to escitalopram |
|
|
| Ongoing | 3 | 500 | Europe | S20098, S20098, Capsule, VALDOXAN, SEROPLEX, CIPRALEX | Institut de Recherches Internationales Servier, SRDL, Servier Research and Develpment | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2006-006540-54: Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day).Twelve-week treatment plus double-blind extension for 12 weeks. |
|
|
| Ongoing | 3 | 100 | Europe | S20098, S20098, CIPRALEX, CIPRALEX | Institut de Recherches Internationales Servier, Servier Research and Development Limited | Major Depressive Disorder | | | | |
2008-003421-17: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder.A 12-week randomised, double-blind, placebo-controlled, with paroxetine (20 mg/day with potential progressive blinded adjustment to 40 mg/day) as validator, 3-arm parallel groups, international multicenter study. |
|
|
| Ongoing | 3 | 40 | Europe | S20098, S20098, SEROXAT, SEROXAT | Institut de Recherches Internationales Servier | Generalized Anxiety Disorder | | | | |
2015-002181-23: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depressive Disorder. |
|
|
| Ongoing | 3 | 484 | Europe, RoW | Agomelatine, Fluoxetine, S20098, Film-coated tablet, Oral solution, Valdoxan, Fluoxetine | Institut de Recherche International Servier, ADIR | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2011-003313-42: Agomelatine efficacy of the drug to improve sleep problems in autistic people Eficacia del fármaco agomelatina para mejorar los problemas del sueño en personas autistas |
|
|
| Ongoing | 2 | 40 | Europe | Agomelatine, Tablet, Valdoxan 25mg | Hospital General Universitario de Alicante, Hospital General Universitario de Alicante | The treatment of sleep disorders in patients with autism spectrum disorders (ASD) El tratamiento de los trastornos del sueño en los pacientes con trastornos del espectro autista (TEA), The treatment of sleep problems in autistic patients El tratamiento de los problemas del sueño en los pacientes autistas, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2004-002577-23: Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose double-blind, placebo-controlled, parallel groups, international study. |
|
|
| Ongoing | 2 | 80 | Europe | S20098-F55, | Institut de Recherches Internationales Servier | Generalised Anxiety Disorder | | | | |
2007-005564-27: Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral activity measured by functional MRI during processing of emotional stimuli in patients with Major Depressive Disorder. A randomised, double-blind, placebo-controlled study with an open extension period of 6 months with agomelatine (25 mg).Comparison to functional MRI profiles of healthy volunteers. |
|
|
| Ongoing | 2 | 60 | Europe | S20098, S20098, | Institut de Recherches Internationales Servier | Major Depressive Disorder | | | | |
| Completed | 1 | 16 | | a single oral dose of 25mg agomelatine | the Third Xiangya Hospital of Central South University; the Third Xiangya Hospital of Central South University, This work was supported by the National Scientific Foundation of China (No. 81373476, 81302851, 81301924) | depression | | | | |
ChiCTR-TRC-13003179: The different effects of agomelatine and escitalopram on the circadian rhythmic system in the first episode depressive patients |
|
|
| Completed | 1 | 90 | | agomelatine 25-50mg per day before sleep ;escitalopram 10-20mg per day after breakfast ;No intervention | National Institute on Drug Dependence, Peking University; Level of the institution:, Natural Science Foundation of China | Depression | | | | |
ChiCTR-IOR-17013734: The control study of mirtazapine and agomelatine on insomnia symptoms in patients with major depressive disorder |
|
|
| Completed | N/A | 30 | | mirtazapine versus agomelatine | Peking University Sixth Hospital; Peking University Sixth Hospital, self fund project | major depressive disorder | | | | |
ChiCTR2000031387: A retrospective study for the liver safety of agomelatine in the treatment of depression in the real world was analyzed based on the big data model algorithm |
|
|
| Not yet recruiting | N/A | 50000 | | N/A ;N/A | Peking University Sixth Hospital; Peking University Sixth Hospital, Horizontal topic | Depressive disorder | | | | |
ChiCTR2000037370: A randomized controlled clinical study on the improvement of cognitive impairment in patients with schizophrenia by replacing BDZ with agomelatin |
|
|
| Recruiting | N/A | 100 | | Agomelatine ;No intervention | Shanghai Mental Health Center; Shanghai Mental Health Center, Shanghai Shenkang Hospital Development Center | Schizophrenia | | | | |
ChiCTR2100046289: Efficacy and safety of agomelatine in patients epilepsy coexisting with depression on mood and cognitive function |
|
|
| Recruiting | N/A | 50 | | placebo pill ;agomelatine 25mg ;agomelatine 50mg | Xuanwu Hospital Capital Medical University; Xuanwu Hospital Capital Medical University, research projects | Epilepsy with depression | | | | |
NCT05952713: Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder |
|
|
| Completed | N/A | 73336 | Europe | Antidepressant, sertraline, citalopram, fluoxetine, paroxetine, escitalopram, reboxetine, venlafaxine, duloxetine, mirtazapine, vortioxetine, agomelatine, amitriptyline, imipramine | Mental Health Services in the Capital Region, Denmark, University of Copenhagen | Major Depressive Disorder | 07/23 | 07/23 | | |
ChiCTR2000034739: Study on the optimization of treatment scheme for patients with chronic insomnia |
|
|
| Not yet recruiting | N/A | 180 | | trazodone ;Mirtazapine ;Fluvoxamine ;CBTI combined with hypnotic therapy ;Agomelatine ;nothing | The Second Affiliated Hospital of Xinxiang Medical University; The Second Affiliated Hospital of Xinxiang Medical University, Not available | Non-organic insomnia | | | | |
| Recruiting | N/A | 120 | | Agomelatine ;none | The Second Affiliated Hospital of Xinxiang Medical College; The Second Affiliated Hospital of Xinxiang Medical University, The Second Affiliated Hospital of Xinxiang Medical University | Schizophrenia | | | | |
ChiCTR2200065883: Effects of agomelatine on occurrence of sleep bruxism: preliminary findings |
|
|
| Not yet recruiting | N/A | 34 | | Placebo intervention + Agomelatine intervention at least 24 hours after placebo intervention ;Agomelatine intervention + Placebo intervention at least 24 hours after agomelatine intervention | Jiangxi Provincial People's Hospital; Jiangxi Provincial People's Hospital, Jiangxi Provincial People's Hospital Grant 2019-009 | Sleep bruxism | | | | |
NCT06120543: CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression |
|
|
| Not yet recruiting | N/A | 50 | NA | | Affiliated Hospital of Nantong University | Polymorphism, Genetic, Depression, CYP1A2 Polymorphism, CYP2C9 Polymorphism, Polymerase Chain Reaction, Plasma Concentration | 12/24 | 03/25 | | |
ChiCTR2300075165: Efficacy and Safety of Agomelatine in Epilepsy Patients With Inpaired Sleep and Mood Disorders: an Observational,Open,and Retrospective study |
|
|
| Recruiting | N/A | 280 | | None; None | Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital, None | Epilepsy Patients With Inpaired Sleep and Mood Disorders | | | | |